Clinical Trial Update: Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects [Phase 4]

View source ↗

Summary

Phase 4 trial investigating dApagliflozin for reducing albuminuria and normalizing hemodynamic function in focal segmental glomerulosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Focal Segmental Glomerulosclerosis | Phase 4 | Status: COMPLETED